Stoke Therapeutics (STOK)
(Real Time Quote from BATS)
$14.86 USD
-0.35 (-2.30%)
Updated Jun 7, 2024 03:54 PM ET
After-Market: $14.85 -0.01 (-0.07%) 4:12 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Stoke Therapeutics, Inc. [STOK]
Reports for Purchase
Showing records 61 - 80 ( 92 total )
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Progress Across Pipeline With Focus on Dravet; Reiterate Buy and $70 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Upgrading To Outperform; The Waiting Is The Hardest Part
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
New POC Data Helps to De-Risk OPA-1 Program - Our Thoughts
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
STOKE Marches On With the MAD Study: 4Q20 Update
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Moving To Neutral; Just Can''t Keep Up With This MONARCH
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Assuming Coverage with a Buy and $70 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MONARCH Presses Forward As OPA1 Nominated As Next Target
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Moving Right Along - MONARCH, Preclinical Updates Paint Positive Picture
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Our Thoughts on GoF SCN1A Following Recent Preclinical Publication
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Delving Virtually Into the Epilepsy Therapeutics Pipeline
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
PacGrow Healthcare Conference: Day 1 - 2 Recap
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
It Takes Two to TANGO; Nature Comms Publication of STK-001 MOA
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Initiation of MONARCH Part A Imminent, Pandemic Impact on Intrathecal Dosing to Be Determined
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
OPA(1)! Marching Towards MONARCH, As Pipeline Progresses
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L